Bio€quity Europe recap, part 2: leadership amid turmoil & start-up talent
Shorla’s Sharon Cunningham, BII’s Bobby Soni discuss a CEO’s role in a downturn, untapped talent pools and the Irish bio-ecosystem
Ensuring that a biotech reaches its key inflection points as effectively as possible during the ongoing capital crunch affects a company across the board, including its people, pipeline and financing toolkit, Shorla’s Sharon Cunningham said on a special edition of the BioCentury This Week podcast. Cunningham and BII’s Bobby Soni joined the BioCentury podcast team to discuss navigating the downturn as a CEO of a private biotech, the untapped talent pools able to run start-ups and the ecosystem in Bio€quity Europe’s next site, Ireland.
BioCentury Associate Editor Stephen Hansen opened the podcast, which recapped the final day of the Bio€quity Europe conference in Milan, by discussing the “Capital Markets Showcase: Surviving a Bear Attack” panel, detailing the variety of ways companies are financing themselves during the down market.
Cunningham, co-founder & CEO of Shorla Pharma Ltd. (dba Shorla Oncology), gave a CEO’s perspective on navigating the extended downturn facing public biotechs. She stressed the importance of having a “cash conservation mindset” in which the company needs to forecast its runway further into the future than was previously necessary, and potentially identify areas where pipeline priorities need to shift.